Business Description
Samsung BioLogics Co Ltd
ISIN : KR7207940008
Compare
Compare
Traded in other countries / regions
207940.Korea IPO Date
2016-11-10Description
Founded in 2011, Samsung Biologics is a South Korean contract development and manufacturing organization with a global client base. Europe and the US contribute 90% of its total revenue. It provides end-to-end development and manufacturing services from cell line developments to final commercial manufacturing. As of 2023, Samsung Biologics had a total production capacity of 604,000 liters, one of the largest in the world. Its CDMO services account for 72.4% of its total revenue. The balance comes from subsidiary Samsung Bioepis, acquired in 2022. Samsung Bioepis is involved in developing and manufacturing biosimilars.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.93 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.16 | |||||
| Debt-to-EBITDA | 0.84 | |||||
| Interest Coverage | 20.26 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 8.12 | |||||
| Beneish M-Score | -2.21 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 43.9 | |||||
| 3-Year EBITDA Growth Rate | 55.1 | |||||
| 3-Year EPS without NRI Growth Rate | 48.7 | |||||
| 3-Year FCF Growth Rate | 114.3 | |||||
| 3-Year Book Growth Rate | 26.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 20.18 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 16.26 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.3 | |||||
| 9-Day RSI | 41.87 | |||||
| 14-Day RSI | 46.36 | |||||
| 6-1 Month Momentum % | 29.57 | |||||
| 12-1 Month Momentum % | 41.7 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.35 | |||||
| Quick Ratio | 0.66 | |||||
| Cash Ratio | 0.39 | |||||
| Days Inventory | 456.89 | |||||
| Days Payable | 31.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.1 | |||||
| Shareholder Yield % | 0.81 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 50.13 | |||||
| Operating Margin % | 31.45 | |||||
| Net Margin % | 24.42 | |||||
| FCF Margin % | 22.81 | |||||
| ROE % | 10.49 | |||||
| ROA % | 6.39 | |||||
| ROIC % | 7.29 | |||||
| 3-Year ROIIC % | 7.22 | |||||
| ROC (Joel Greenblatt) % | 30.7 | |||||
| ROCE % | 12.03 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 69.76 | |||||
| Forward PE Ratio | 57.67 | |||||
| PE Ratio without NRI | 69.97 | |||||
| Shiller PE Ratio | 132.83 | |||||
| Price-to-Owner-Earnings | 52.68 | |||||
| PEG Ratio | 1.78 | |||||
| PS Ratio | 17.04 | |||||
| PB Ratio | 6.95 | |||||
| Price-to-Tangible-Book | 15.63 | |||||
| Price-to-Free-Cash-Flow | 74.67 | |||||
| Price-to-Operating-Cash-Flow | 43.38 | |||||
| EV-to-EBIT | 49.82 | |||||
| EV-to-Forward-EBIT | 43.65 | |||||
| EV-to-EBITDA | 35.67 | |||||
| EV-to-Forward-EBITDA | 30.88 | |||||
| EV-to-Revenue | 17.06 | |||||
| EV-to-Forward-Revenue | 13.62 | |||||
| EV-to-FCF | 74.05 | |||||
| Price-to-Projected-FCF | 7.54 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.8 | |||||
| Price-to-Graham-Number | 6.97 | |||||
| Earnings Yield (Greenblatt) % | 2.01 | |||||
| FCF Yield % | 1.33 | |||||
| Forward Rate of Return (Yacktman) % | 20.2 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Samsung BioLogics Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 4,211,289.666 | ||
| EPS (TTM) (â‚©) | 14449 | ||
| Beta | 0.4 | ||
| Volatility % | 34.17 | ||
| 14-Day RSI | 46.36 | ||
| 14-Day ATR (â‚©) | 35760.164209 | ||
| 20-Day SMA (â‚©) | 1035950 | ||
| 12-1 Month Momentum % | 41.7 | ||
| 52-Week Range (â‚©) | 698000 - 1113000 | ||
| Shares Outstanding (Mil) | 71.17 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Samsung BioLogics Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Samsung BioLogics Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Samsung BioLogics Co Ltd Frequently Asked Questions
What is Samsung BioLogics Co Ltd(XKRX:207940)'s stock price today?
The current price of XKRX:207940 is â‚©1008000.00. The 52 week high of XKRX:207940 is â‚©1113000.00 and 52 week low is â‚©698000.00.
When is next earnings date of Samsung BioLogics Co Ltd(XKRX:207940)?
The next earnings date of Samsung BioLogics Co Ltd(XKRX:207940) is 2025-01-24 Est..
Does Samsung BioLogics Co Ltd(XKRX:207940) pay dividends? If so, how much?
Samsung BioLogics Co Ltd(XKRX:207940) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers